Alaunos Therapeutics, Inc. (TCRT)
Largest Insider Buys in Sector
TCRT Stock Price History Chart
TCRT Stock Performance
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Insider Activity of Alaunos Therapeutics, Inc.
Over the last 12 months, insiders at Alaunos Therapeutics, Inc. have bought $0 and sold $6,022 worth of Alaunos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Alaunos Therapeutics, Inc. have bought $969,543 and sold $152,939 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 750,000 shares for transaction amount of $487,500 was made by Postma Robert W (director) on 2022‑11‑29.
List of Insider Buy and Sell Transactions, Alaunos Therapeutics, Inc.
| 2024-12-31 | Sale | director | 3,000 0.1921% | $2.01 | $6,022 | -1.57% | ||
| 2023-09-01 | Sale | Chief Executive Officer | 68,014 0.0277% | $0.14 | $9,542 | -40.66% | ||
| 2022-11-29 | director | 750,000 0.3334% | $0.65 | $487,500 | -26.47% | |||
| 2022-11-29 | director | 1.25M 0.5557% | $0.65 | $812,500 | -26.47% | |||
| 2021-12-22 | Sale | EVP, Operations | 20,132 0.0094% | $1.27 | $25,568 | -25.70% | ||
| 2021-11-17 | Chief Executive Officer | 9,116 0.0044% | $1.40 | $12,762 | -20.22% | |||
| 2021-11-16 | Chief Executive Officer | 884 0.0004% | $1.40 | $1,238 | -22.70% | |||
| 2021-09-29 | director | 100,000 0.0464% | $1.91 | $191,000 | -40.63% | |||
| 2021-09-02 | director | 75,000 0.0342% | $1.73 | $129,750 | -35.59% | |||
| 2021-09-02 | director | 23,770 0.011% | $1.76 | $41,835 | -35.59% | |||
| 2021-09-01 | director | 50,000 0.0238% | $1.83 | $91,500 | -36.31% | |||
| 2021-09-01 | director | 100,000 0.0445% | $1.71 | $171,000 | -36.31% | |||
| 2021-01-08 | Sale | EVP, GM Gene Therapy | 27,894 0.0129% | $3.12 | $87,029 | -22.47% | ||
| 2021-01-08 | Sale | General Counsel and Secretary | 26,500 0.0122% | $3.12 | $82,680 | -22.47% | ||
| 2021-01-08 | Sale | SVP, Treasurer & CAO | 18,020 0.0082% | $3.09 | $55,682 | -22.47% | ||
| 2021-01-04 | Sale | President and CEO | 105,693 0.0475% | $2.71 | $286,428 | -9.93% | ||
| 2021-01-04 | Sale | EVP, GM Cell Therapy | 21,620 0.0097% | $2.72 | $58,806 | -9.93% | ||
| 2020-01-02 | Sale | President | 22,394 0.011% | $4.55 | $101,893 | -37.61% | ||
| 2020-01-02 | Sale | EVP, GM Cell Therapy | 24,890 0.0123% | $4.55 | $113,250 | -37.61% | ||
| 2020-01-02 | Sale | EVP, GM Gene Therapy | 27,923 0.0138% | $4.55 | $127,050 | -37.61% |
Insider Historical Profitability
| Vieser Jaime | director | 25894 1.6171% | $1.70 | 2 | 1 | <0.0001% |
| Postma Robert W | director | 5000000 312.256% | $1.70 | 2 | 0 | <0.0001% |
| Cooper Laurence James Neil | President and CEO | 1799280 112.3672% | $1.70 | 1 | 2 | <0.0001% |
| Boyle Kevin S. Sr. | Chief Executive Officer | 798236 49.8508% | $1.70 | 2 | 1 | <0.0001% |
| De Groot Eleanor | EVP, Operations | 237106 14.8076% | $1.70 | 0 | 3 | |
| Buck Jill | EVP, GM Gene Therapy | 199516 12.46% | $1.70 | 0 | 2 | |
| MAUNEY DAVID M MD | President | 195278 12.1953% | $1.70 | 1 | 1 | <0.0001% |
| Hagen Heidi | director | 145889 9.1109% | $1.70 | 1 | 0 | <0.0001% |
| WEISER MICHAEL | director | 135945 8.4899% | $1.70 | 0 | 1 | |
| Hadfield Robert | General Counsel and Secretary | 133319 8.3259% | $1.70 | 0 | 2 | |
| Weis Holger | director | 120167 7.5046% | $1.70 | 1 | 0 | <0.0001% |
| Huang James | director | 108333 6.7655% | $1.70 | 1 | 0 | <0.0001% |
| KIRK RANDAL J | 100000 6.2451% | $1.70 | 14 | 0 | +1.39% | |
| Fowler Wyche | director | 72500 4.5277% | $1.70 | 1 | 0 | +0.2% |
| Lafond Kevin G | SVP, Treasurer & CAO | 63965 3.9947% | $1.70 | 0 | 4 | |
| BELBEL CAESAR J | COO, CLO, and Secretary | 59201 3.6972% | $1.70 | 0 | 1 | |
| BRENNAN MURRAY | director | 12500 0.7806% | $1.70 | 0 | 3 | |
| LEBEL FRANCOIS | Executive Vice President R&D | 0 0% | $1.70 | 0 | 1 |